A pioneer in innovative imaging services and device software, Median Technologies (Median) leverages cutting-edge Artificial Intelligence (AI) technologies to increase the accuracy of early diagnosis and treatment of many cancers. Median's offerings, iCRO for the analysis and management of medical images in oncology clinical trials and eyonisTM, a suite of medical device software based on AI technologies, enable biopharmaceutical companies and clinicians to advance patient care and accelerate the development of new therapies. Median is also present in the United States and China.

Employees

211

Sector

Advanced Medical Equipment & Technology

Calendar

23/04 - Earnings release - Annual 2025

More about the company

Quotes

Date	Price	Change	Volume
13/26/13	4.680 €	-3.01%	2,67,634
12/26/12	4.825 €	-3.02%	2,33,745
11/26/11	4.975 €	-3.96%	2,78,941
10/26/10	5.180 €	+2.17%	1,86,939
09/26/09	5.070 €	-1.36%	2,97,176

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.680EUR

Average target price

12.75EUR

Spread / Average Target

+172.44%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 10:25:00 13/03/2026 pm IST			5-day change	1st Jan Change
4.680 ^EUR	-3.01%		-8.95%	-1.16%

02/03	Median Technologies to Showcase Eyonis®? LCS , Its AI/ML-Based Software as A Medical Device for Lung Cancer Screening, At the European Congress of Radiology	CI
19/02	Air France-KLM, Renault, Pernod Ricard... Stocks to Watch Today in Paris

Capitalization	18Cr 20Cr 16Cr 15Cr 28Cr 1.86TCr 29Cr 190.11Cr 75Cr 890.48Cr 76Cr 74Cr 3.22TCr	P/E ratio 2025 *	-8.68x	P/E ratio 2026 *	-11.2x
Enterprise value	20Cr 22Cr 18Cr 17Cr 31Cr 2.07TCr 32Cr 210.68Cr 83Cr 986.82Cr 84Cr 82Cr 3.56TCr	EV / Sales 2025 *	8.34x	EV / Sales 2026 *	6.29x
Free-Float	73.77%	Yield 2025 *	-	Yield 2026 *	-

02/03	Median Technologies to Showcase Eyonis®? LCS , Its AI/ML-Based Software as A Medical Device for Lung Cancer Screening, At the European Congress of Radiology	CI
19/02	Air France-KLM, Renault, Pernod Ricard... Stocks to Watch Today in Paris
18/02	Median Technologies Launches Eyonis® Lcs Software for Lung Cancer Screening Following Fda Clearance	CI
18/02	Median Technologies Appoints Oran Muduroglu as President and Executive Chairman of Median Eyonis Inc	CI
18/02	ADP, Vinci, Orange ...Stocks to Watch Tomorrow in Paris
18/02	An Appointment to Lead Median's American Subsidiary
13/02	Median Technologies Announces Its Non-Exclusive Distribution Agreement with Tempus Ai, Inc	CI
13/02	Tempus AI, Inc. Announces Collaboration with Median Technologies to Integrate AI-Powered Lung Cancer Screening into the Pixel Platform	CI
09/02	Median Technologies Soars After Receiving FDA 510(k) Clearance
09/02	Median Technologies Receives FDA 510(K) Clearance for eyonis®? LCS, the First AI Tech-Based Detection and Diagnosis Device for Lung Cancer Screening	CI
19/01	Median Technologies Slips After Activity Update, Despite Positive Analyst Outlook
19/01	Median Technologies reports FY revenue EUR 23.5 million	RE
09/12	Stifel Reiterates Buy Recommendation on Median Technologies Following Distribution Agreement

19/01	Median Technologies Slips After Activity Update, Despite Positive Analyst Outlook
09/12	Stifel Reiterates Buy Recommendation on Median Technologies Following Distribution Agreement
23/25/23	Median Technologies reports Q3 rev EUR 5.9 mln	RE
07/21/07	Analyst recommendations: Amgen, Banner, Merck, Oracle, Phoenix...
11/21/11	Today's analyst recommendations: Activision Blizzard, Cisco, Nikola, Nutrien, Shake Shack...

Median Technologies Share Price

Equities

ALMDT

FR0011049824

Advanced Medical Equipment & Technology

Valuation: Median Technologies

Chart: Median Technologies

Latest news: Median Technologies

Analysts' recommendations: Median Technologies

Press Releases: Median Technologies

News in other languages: Median Technologies

Quotes and Performance

Course Extremes

Managers and Directors: Median Technologies

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise

13/03	Median Technologies Meets the Eligibility Conditions for the PEA-PME Scheme	BU
04/03	Median Technologies : Corporate Update – March 2026 (TD Cowen Conference)	PU
02/03	Median Technologies to Showcase eyonis® LCS, Its AI/ML-based Software as a Medical Device for Lung Cancer Screening, at the European Congress of Radiology	BU
28/02	Median Technologies : Inside Information / Other news releases	PU
27/02	Median Technologies to present at the TD Cowen 46th Annual Health Care Conference	BU

13/03	Median Technologies répond aux conditions d’éligibilité du dispositif PEA-PME
02/03	Median Technologies présentera eyonis® LCS, son logiciel dispositif médical basé sur l’IA et le Machine Learning (ML) pour le dépistage du cancer du poumon, au Congrès Européen de Radiologie
28/02	Median Technologies : Informations privilégiées / Autres communiqués
27/02	Median Technologies fera une présentation à la 46ème conférence annuelle Health Care de TD Cowen
23/02	Median Technologies tiendra deux webconférences pour présenter les avancées stratégiques soutenant le déploiement commercial d’eyonis® LCS aux États‑Unis

1 day	-3.01%
1 week	-8.95%
Current month	-3.60%
1 month	-14.29%
3 months	+47.87%
6 months	+43.34%
Current year	-1.16%

1 week	4.63	5.24
1 month	4.53	5.6
Current year	3.85	7.27
1 year	1.19	7.27
3 years	1.19	8.66
5 years	1.19	18.32
10 years	0.9	18.32

Manager	Title	Age	Since
Fredrik Brag CEO	Chief Executive Officer	64	01/01/2002
Jean-Christophe Montigny DFI	Director of Finance/CFO	-	12/07/2021
Emmanuelle Leygues IRC	Investor Relations Contact	-	01/04/2019

Director	Title	Age	Since
Fredrik Brag CHM	Chairman	64	01/01/2002
Oran Muduroglu CHM	Chairman	63	10/04/2019
Kapil Dhingra BRD	Director/Board Member	66	01/06/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MEDIAN TECHNOLOGIES	-3.01%	-8.95%	+74.95%	-40.00%	20Cr
THERMO FISHER SCIENTIFIC, INC.	-2.32%	-7.49%	-11.05%	-16.47%	17TCr
INTUITIVE SURGICAL, INC.	-1.48%	-3.67%	-2.53%	+100.68%	17TCr
DANAHER CORPORATION	+0.57%	-4.18%	-11.11%	-23.50%	13TCr
BOSTON SCIENTIFIC CORPORATION	+0.85%	-3.11%	-28.85%	+43.10%	10TCr
SIEMENS HEALTHINEERS AG	-0.64%	-4.03%	-25.77%	-22.13%	4.95TCr
EDWARDS LIFESCIENCES CORPORATION	-3.31%	+0.21%	+18.07%	+4.62%	4.75TCr
RESMED, INC.	-0.68%	-8.71%	+2.98%	+10.69%	3.35TCr
GE HEALTHCARE TECHNOLOGIES INC.	+0.63%	-4.71%	-13.66%	-8.26%	3.23TCr
AGILENT TECHNOLOGIES, INC.	-0.11%	-3.09%	-7.98%	-19.43%	3.15TCr
Average	-0.95%	-4.77%	-0.50%	+2.93%	7.7TCr
Weighted average by Cap.	-0.88%	-4.56%	-10.08%	+18.12%

	2025 *	2026 *
Net sales	2.34Cr 2.68Cr 2.11Cr 2.02Cr 3.68Cr 247.7Cr 3.83Cr 25Cr 10Cr 118.34Cr 10Cr 9.84Cr 427.42Cr	3.17Cr 3.63Cr 2.87Cr 2.74Cr 4.99Cr 335.94Cr 5.19Cr 34Cr 14Cr 160.5Cr 14Cr 13Cr 579.69Cr
Net income	-1.94Cr -2.22Cr -1.75Cr -1.68Cr -3.05Cr -205.36Cr -3.17Cr -21Cr -8.3Cr -98Cr -8.33Cr -8.16Cr -354.36Cr	-1.21Cr -1.38Cr -1.09Cr -1.05Cr -1.9Cr -128.05Cr -1.98Cr -13Cr -5.18Cr -61Cr -5.19Cr -5.09Cr -220.95Cr
Net Debt	1.91Cr 2.18Cr 1.72Cr 1.65Cr 3Cr 201.65Cr 3.11Cr 21Cr 8.15Cr 96Cr 8.18Cr 8.01Cr 347.96Cr	2.35Cr 2.69Cr 2.13Cr 2.03Cr 3.7Cr 249Cr 3.85Cr 25Cr 10Cr 118.96Cr 10Cr 9.89Cr 429.67Cr